Select publications

Publications discussed by Dr Jordan

Howell A et al. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 1992; 3: 611-7. Abstract

Lonning PE et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001;67(2):111-6. Abstract

Song RX et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 2001;93(22):1714-23. Abstract

Tamoxifen resistance

Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002;2(2):101-12. Abstract

de Lima GR, Facina G, Shida JY, Chein MB, Tanaka P, Dardes RC, Jordan VC, Gebrim LH. Effects of low dose tamoxifen on normal breast tissue from premenopausal women. Eur J Cancer 2003 May;39(7):891-8. Abstract.

Goss PE and Strasser K. Tamoxifen resistant and refractory breast cancer: The value of aromatase inhibitors. Drugs 2002;62(6):957-66. Abstract

Hendrich AB, Michalak K. Lipids as a target for drugs modulating multidrug resistance of cancer cells. Curr Drug Targets 2003;4(1):23-30. Abstract

Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE, Nicholson RI. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat. 2003 Sep;81(1):81-93. Abstract.

Jensen EV, Jordan VC. The estrogen receptor: A model for molecular medicine. Clin Cancer Res. 2003 Jun;9(6):1980-9. Abstract.

Johnston SR et al. Integration of signal transduction inhibitors with endocrine therapy: An approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 2003;9(1 Pt 2):524S-32S. Abstract

Kurokawa H, Arteaga CL. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 2003;9(1 Pt 2):511S-5S. Abstract

Murphy LC, Leygue E, Niu Y, Snell L, Ho SM, Watson PH. Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer. 2002 Dec 2;87(12):1411-6. Abstract.

Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 5;95(5):353-61. Abstract.

Schapira M. Pharmacogenomics opportunities in nuclear receptor targeted cancer therapy. Curr Cancer Drug Targets 2002;2(3):243-56. Abstract

Schiff R et al. Breast cancer endocrine resistance: How growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003;9(1 Pt 2):447S-54S. Abstract

Home · Search